165 related articles for article (PubMed ID: 27538919)
1. The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model.
Takano J; Maeda K; Bolger MB; Sugiyama Y
Drug Metab Dispos; 2016 Nov; 44(11):1808-1818. PubMed ID: 27538919
[TBL] [Abstract][Full Text] [Related]
2. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
[TBL] [Abstract][Full Text] [Related]
3. The Consequence of Drug-Drug Interactions Influencing the Interplay between P-Glycoprotein and Cytochrome P450 3a: An Ex Vivo Study with Rat Precision-Cut Intestinal Slices.
Li M; de Graaf IA; Siissalo S; de Jager MH; van Dam A; Groothuis GM
Drug Metab Dispos; 2016 May; 44(5):683-91. PubMed ID: 26932816
[TBL] [Abstract][Full Text] [Related]
4. Significance of Basal Membrane Permeability of Epithelial Cells in Predicting Intestinal Drug Absorption.
Yoshitomo A; Asano S; Hozuki S; Tamemoto Y; Shibata Y; Hashimoto N; Takahashi K; Sasaki Y; Ozawa N; Kageyama M; Iijima T; Kazuki Y; Sato H; Hisaka A
Drug Metab Dispos; 2023 Mar; 51(3):318-328. PubMed ID: 36810197
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism.
Dufek MB; Knight BM; Bridges AS; Thakker DR
Drug Metab Dispos; 2013 Mar; 41(3):642-50. PubMed ID: 23288866
[TBL] [Abstract][Full Text] [Related]
6. Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values.
Tachibana T; Kato M; Sugiyama Y
Pharm Res; 2012 Mar; 29(3):651-68. PubMed ID: 21913031
[TBL] [Abstract][Full Text] [Related]
7. Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.
Dufek MB; Bridges AS; Thakker DR
Drug Metab Dispos; 2013 Sep; 41(9):1695-702. PubMed ID: 23821186
[TBL] [Abstract][Full Text] [Related]
8. Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A.
Johnson BM; Charman WN; Porter CJ
Drug Metab Dispos; 2003 Sep; 31(9):1151-60. PubMed ID: 12920171
[TBL] [Abstract][Full Text] [Related]
9. Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition.
Zhao G; Huang J; Xue K; Si L; Li G
Eur J Pharm Sci; 2013 Nov; 50(3-4):429-39. PubMed ID: 23981337
[TBL] [Abstract][Full Text] [Related]
10. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
11. A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum.
Johnson BM; Chen W; Borchardt RT; Charman WN; Porter CJ
J Pharmacol Exp Ther; 2003 Apr; 305(1):151-8. PubMed ID: 12649363
[TBL] [Abstract][Full Text] [Related]
12. Determinants of Intestinal Availability for P-glycoprotein Substrate Drugs Estimated by Extensive Simulation With Mathematical Absorption Models.
Ando H; Hatakeyama H; Sato H; Hisaka A; Suzuki H
J Pharm Sci; 2017 Sep; 106(9):2771-2779. PubMed ID: 28479352
[TBL] [Abstract][Full Text] [Related]
13. [Regulatory mechanisms of gut microbiota on intestinal CYP3A and P-glycoprotein in rats with dextran sulfate sodium-induced colitis].
Gao XJ; Li T; Wei B; Yan ZX; Yan R
Yao Xue Xue Bao; 2017 Jan; 52(1):34-43. PubMed ID: 29911375
[TBL] [Abstract][Full Text] [Related]
14. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
15. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
Yamazaki S; Loi CM; Kimoto E; Costales C; Varma MV
Drug Metab Dispos; 2018 Aug; 46(8):1200-1211. PubMed ID: 29739809
[TBL] [Abstract][Full Text] [Related]
16. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the effect of the uneven distribution of CYP3A4 and P-glycoprotein in the intestine on the barrier function against xenobiotics: a simulation study.
Watanabe T; Maeda K; Nakai C; Sugiyama Y
J Pharm Sci; 2013 Sep; 102(9):3196-204. PubMed ID: 23754337
[TBL] [Abstract][Full Text] [Related]
18. Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal-systemic concentration difference method.
Kadono K; Koakutsu A; Naritomi Y; Terashita S; Tabata K; Teramura T
Xenobiotica; 2014 Jun; 44(6):511-21. PubMed ID: 24329478
[TBL] [Abstract][Full Text] [Related]
19. Baicalin pharmacokinetic profile of absorption process using novel in-vitro model: cytochrome P450 3A4-induced Caco-2 cell monolayers combined with rat intestinal rinse fluids.
Morisaki T; Hou XL; Takahashi K; Takahashi K
J Pharm Pharmacol; 2013 Oct; 65(10):1526-35. PubMed ID: 24028620
[TBL] [Abstract][Full Text] [Related]
20. CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib.
De Buck S; Kucher K; Hara H; Gray C; Woessner R
Biopharm Drug Dispos; 2018 Sep; 39(8):394-402. PubMed ID: 30171694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]